Tagged with Lilly

China Established in December 2012, in less than a decade, Chinese biotech Junshi Biosciences has already transformed itself into a publicly-listed commercial company with a successful USD 450 million IPO on the Hong Kong Stock Exchange and their first product, toripalimab, being the first anti-PD-1 monoclonal antibody self-developed by a Chinese…

Long Read Accounting for less than two percent of the global pharmaceutical market, the Middle East has long been somewhat overlooked by many drug makers, most of whom seemed more intent on chasing demand in the decidedly more populous Asian market space. But, with an estimated annual growth rate of 10 percent,…

Coronavirus During a global virtual press briefing on 19 March 2020, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) gathered five global pharmaceutical leaders including Eli Lilly Chairman and CEO David A. Ricks, who is also the president of IFPMA for 2019-2020, to discuss the global ramifications of the COVID-19…

Coronavirus The CEOs and top executives, David Ricks, chairman and CEO, Eli Lilly & Co and IFPMA president, Severin Schwan, CEO, Roche, Paul Stoffels, chief scientific officer, Johnson & Johnson, David Loew, executive VP, Sanofi Pasteur and Rajeev Venkayya, president, Global Vaccines Business Unit, Takeda took part in a virtual press…

Romania Attila Fejer general manager of Eli Lilly in Romania gives his insights on the “deadly cocktail” of challenging policies that govern the pharmaceutical industry in the country. He shares the new therapeutic direction that Lilly has taken by moving into rheumatology and dermatology. Additionally, he points to the change in…

UAE From Turkey to Tajikistan, Bangladesh to Bahrain, and Russia to Rwanda, multinational pharma firms are increasingly situating wide-ranging management responsibilities in the UAE. The following is an inexhaustive list of some of the widely varying geographies being managed from the UAE, as well as insights from the executives overseeing them.…

UAE Eli Lilly’s president and general manager for the SAMETA (South Asia, Middle East, Turkey, and Africa) region, José Antonio Alas, discusses the challenges attached to overseeing 70 countries and half of the world’s population, the main opportunities for Lilly’s diabetes and oncology portfolio in the region, and the importance of…

Czech Republic Miha Kline has been with Eli Lilly for the past 15 years, becoming Country Manager Czech Republic and Slovakia four years ago. Kline shares his milestones with the affiliate successfully entering new therapeutic areas and reaching 1bn CZK in sales. Kline also discusses the challenging market access conditions and the…

Korea Multinational pharma company managers working abroad must adapt to new cultures and develop a deep understanding of local markets. Korea is no different; here three foreign country managers give their first impressions and insights into the Korean pharma market.   Nic Horridge, Roche   As a newcomer in the land…

China China’s pharma market is growing at an unprecedented pace and has become a key element of virtually all pharma multinationals’ international strategies. However, with a spate of regulatory reforms being rolled out, it can be challenging for large organizations with headquarters located in slower-paced mature markets to adapt to China’s…

Puerto Rico After climbing through the ranks from sales representative to leading business units at Eli Lilly Canada, François Gilbert took the reins of Eli Lilly’s Puerto Rican affiliate last year. Among other things, he shares the reasons why Eli Lilly invests in strong commercial capabilities and clinical operations on the island,…

Puerto Rico Victor Cruz, VP-Manufacturing Puerto Rico and Brazil for Lilly del Caribe highlights the priorities in his new position and underlines the importance of the Carolina facility for the global insulin supply. He also discusses Puerto Rico’s role related to future trends in pharmaceutical manufacturing, such as AI, robotics and continuous…